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doi:10.1016/j.ejvs.2010.07.006Abstract Object: The pathogenesis of carotid artery stenosis (CAS) as well as the mecha-
nisms underlying the different localisation of the atherosclerotic lesions remains poorly under-
stood. We used microarray technology to identify novel systemic mediators that could
contribute to CAS pathogenesis.
Moreover, we compared gene-expression profile of CAS with that of patients affected by
abdominal aortic aneurysm (AAA), previously published by our group.
Methods and results: By global gene-expression profiling in a pool of 10 CAS patients and 10
matched controls, we found 82 genes differentially expressed. Validation study in pools used
for profiling and replication study in larger numbers of CAS patients (n Z 40) and controls
(n Z 40) of 14 genes by real-time polymerase chain reaction (RT-PCR) confirmed microarray
results. Fourteen out of 82 genes were similarly expressed in AAA patients. Gene ontology anal-
ysis identified a statistically significant enrichment in CAS of differentially expressed tran-
scripts involved in immune response and oxygen transport. Whereas alteration of oxygen
transport is a common tract of the two localisations, alteration of immune response in CAS
and of lipid metabolic process in AAA represents distinctive tracts of the two atherosclerotic
diseases.
Conclusions: We describe the systemic gene-expression profile of CAS, which provides an
extensive list of potential molecular markers.
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550 L. Rossi et al.Carotid artery disease is a major cause of ischaemic
1
evaluation, electrocardiogram (ECG), echocardiogram andstroke, and cerebrovascular disease is one of the main
causes of death and disability in developed countries.2
Atherosclerosis is a chronic immune-inflammatory disease
of the arterial wall, where both innate and adaptive
immunologic and inflammatory mechanisms are involved.3
The fine mechanisms underlying carotid artery stenosis
(CAS) pathogenesis as well as the localisation of the
atherosclerotic lesions in different districts of the arterial
tree remain poorly understood.
Several genomic approaches have been applied to
understand the multifactorial nature and different local-
isation of atherosclerosis: these include genome-wide and
candidate gene association, as well as transcriptome and
proteome studies.4 Besides traditional cardiovascular risk
factors, there is a current interest in the identification of
novel molecular risk markers of atherogenesis and
atherothrombosis.
A large number of expression profiling studies has been
conducted over the past few years to investigate the
molecular pathways involved in the onset and progression
of atherosclerosis in CAS as well as other arteries’
diseases.5 Most studies compared whole atherosclerotic
plaques or specific plaque regions to non-diseased arteries/
regions. Transcript levels were analysed to study either the
early phases of atherosclerosis or the progression from
stable to ruptured lesions.5 Few data are available on the
global transcriptomic profile at systemic level.
In this study, we used a gene-expression profiling
approach by using a two-colour microarray technology on
peripheral blood to find possible mediators/markers, at
systemic level, of CAS. In fact, blood is an easy specimen to
obtain that could represent a valuable resource to translate
results in diagnosis and prognosis processes. Moreover,
blood is a fitting surrogate for atherosclerotic tissue,
because it contains the inflammatory cells that are involved
in its pathogenesis.6
Therefore, our study aimed to: (1) identify novel medi-
ators/markers of CAS at the systemic level by studying the
gene-expression profile of peripheral blood of patients with
respect to control subjects; (2) characterise common and
peculiar alterations of the gene-expression profile of CAS
with respect to another atherosclerotic disease, with
a different localisation of the lesions, abdominal aortic
aneurysm (AAA), previously studied by our group.7
Materials and Methods
Subjects
The study group included 50 patients, undergoing carotid
endarterectomy for severe stenosis (>70%) of the extra-
cranial carotid artery, referred to the Vascular Surgery
Department (University of Florence). All the patients were
asymptomatic. Carotid stenosis was assessed by duplex
scanning and confirmed by angiographic computed tomog-
raphy and the degree of the stenosis was defined according
to the North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET) criteria.8 To assess for the presence of
additional atherosclerotic disease, all subjects underwent
clinical and diagnostic examinations, clinical cardiologyperipheral duplex scanning.
A control group of 50 healthy subjects matched for age
and gender were recruited in the same period. The control
group had a negative history of vascular diseases. Controls
were screened for carotid artery disease.
We used a structured questionnaire to identify symptom-
free controls and to exclude subjects, who were suspected
of having any form of arterial or venous vascular disease.
In patients and controls, blood was collected after an
overnight fast. To avoid stress or conditions that may alter
the expression profiles, patients were enrolled during the
presurgical visit (1 month/15 days before surgery).
Hypertension,9 dyslipidaemia10 and diabetes11were
defined according to international guidelines (additional
information in Supplementary Data). The Local Ethics
Committee approved the study, and written informed
consent was obtained from all participants.
To compare CAS gene-expression profiles obtained in the
present study with those of AAA patients obtained in our
previous study,7 we refer to materials and methods reported
in the previous article. To facilitate the comparison of
demographic and clinical characteristics, data on CAS
patients, AAApatients (previous paper)7 and healthy subjects
(present and previous7 paper) are reported in Table 1.
Haematological parameters
Blood samples were taken from all subjects for blood
counts (red blood cells (RBC), white blood cells (WBC),
haemoglobin (Hb), haematocrit (Hct) and reticulocytes)
and for serum erythropoietin (EPO) level measurement.
The RBC, WBC and reticulocyte counts, Hb and Hct were
evaluated using an automated counter, while EPO was
determined by DSL1100 Erythropoietin RIA (Diagnostic
Systems Laboratories, TX, USA).
Total RNA preparation
Total RNA was extracted from venous peripheral blood
using PAXgene Blood RNA Kit (Qiagen, Germany), and RNA
quality and integrity were evaluated by capillary electro-
phoresis with 2100 Bioanalyzer (Agilent, CA, USA) (addi-
tional information in Supplementary Data). Equal aliquots
of RNA from 10 CAS patients and 10 age- and gender-
matched controls were pooled in four different pools,
according to the experimental design reported below.
Experimental design and microarray gene-
expression analysis
We performed two different pools for 10 CAS patients
(nZ 5 patients in pool A and nZ 5 patients in pool B) and
two different pools for 10 healthy subjects (n Z 5 controls
in pool C and nZ 5 controls in pool D). Two replicates (dye
swap) of the two microarray experiments were made.
Microarrays experiments were performed as described in
our previous articles.7,12 We used arrays representing
14 000 genes (70mer oligonucleotides; Human AROS v1.1,
Operon Technologies, CA, USA) (additional information in
Supplementary Data).
Table 1 Demographic and clinical characteristics of CAS and AAA patients and controls used in pools (gene-expression
profiling) and individually (RT-PCR validation analyses on a second larger population).
CAS CAS in pool
(N Z 10)
CTR in pool
(N Z 10)
p CAS patients
(N Z 40)
CTR subjects
(N Z 40)
p
Age 68 (45e81) 68 (44e83) e 69 (45e86) 65 (43e87) e
Sex (male) N (%) 6 (60.0) 6 (60.0) e 27 (67.5)b 23 (57.5) 0.488
Smoking N (%) 7 (70.0) 3 (30.0) 0.179 29 (72.5) 15 (37.5) 0.003
Diabetes N (%) 2 (20.0) 1 (10.0) 1 9 (22.5) 1 (2.5) 0.014
Hypertension N (%) 6 (60.0) 3 (30.0) 0.369 28 (70.0) 10 (25.0) 0.0001
Dyslipidemia N (%) 6 (60.0) 2 (20.0) 0.169 24 (60.0) 4 (10.0) 4.23  106
CAD N (%) 3 (30.0) 0 0.210 8 (20.0) 0 0.053
PAD N (%) 1 (10.0) 0 1 5 (12.5) 0 0.054
COPD N (%) 3 (30.0) 0 0.210 7 (17.5)c 0 0.0117
AAAa AAA in pool
(N Z 10)
CTR in pool
(N Z 10)
p AAA patients
(N Z 36)
CTR subjects
(N Z 36)
p
Age 68 (60e82) 66 (52e85) e 69 (55e84) 70 (52e86) e
Sex (male) N (%) 8 (80.0) 8 (80.0) e 32 (88.9) 32 (88.9) e
Smoking N (%) 8 (80.0) 2 (20.0) 0.012 24 (66.6) 12 (33.3) 0.005
Diabetes N (%) 1 (10.0) 0 0.499 3 (8.3) 0 0.119
Hypertension N (%) 6 (60.0) 2 (20.0) 0.085 27 (75.0) 8 (22.2) 7.46  106
Dyslipidemia N (%) 7 (70.0) 1 (10.0) 0.009 25 (69.4) 2 (5.5) 2.14  108
CAD N (%) 1 (10.0) 0 0.499 13 (36.1) 0 6.80  105
PAD N (%) 1 (10.0) 0 0.499 8 (22.2) 0 0.003
COPD N (%) 6 (60.0) 0 0.005 21 (58.3) 0 5.18  108
CAS Z carotid artery stenosis patients; CTR Z control subjects; AAA Z abdominal aortic aneurysm; CAD Z coronary artery disease;
PAD Z Peripheral arterial occlusive disease; COPD Z chronic obstructive pulmonary disease.
a previous paper.7
b CAS vs AAA p Z 0.03.
c CAS vs AAA p Z 0.0003.
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Scanned images were processed using the GenePix Pro
4.1 software (Axon Instruments, CA, USA). For each
microarray, we performed a local intensity-dependent
normalisation.13
Data matrices obtained from the pre-processing proce-
dure were analysed in R environment (http://www.
r-project.org). Normalisation procedure was done by
Statistical Microarray Analysis (sma) package (http://stat-
www.berkeley.edu/users/terry/zarray/Software/
smacode.html). Due to the Significance Analysis of Micro-
array (SAM)-method requirements, we analysed all the
transcripts that had at least two values out of four for
control and CAS patient pools (analysable transcripts).
Data were then analysed by the SAM algorithm.14 In SAM
analysis, we chose a delta value of 0.8 that allowed us to
identify differentially expressed genes with a false
discovery rate (FDR) of 2.2%. The full data set is available at
ArrayExpress (E-MEXP-2113 in http://www.ebi.ac.uk/
microarray-as/ae/browse.html) (additional information in
Supplementary Data).
Gene ontology analysis
We used the biological process ontology by the Gene
Ontology (GO) consortium.15 The mappings were down-
loaded from ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/
gene2go.gz. Details on GO analysis were reported in our
previous articles.7,12Real-time PCR based gene-expression analysis
Fourteen differentially expressed genes were selected for
validation of microarray analysis using RT-PCR in the
subjects included in the pools or in the 40 patients and 40
controls used individually to replicate data obtained by
microarray experiments. In the selection, we took care to
validate genes with increased and decreased expression in
CAS. We performed TaqMan RT-PCR using TaqMan pre-
developed assays on an ABI Prism 7900 instrument (Applied
Biosystems, CA, USA) to quantify the following genes:
haemoglobin alpha 2 (HBA2), haemoglobin epsilon 1 (HBE1),
haemoglobin theta 1 (HBQ1), dematin (EPB49), glycophorin
c (GYPC ), basigin (BSG), regulator of G-protein signalling 2
(RGS2), major histocompatibility complex, class II, DQ beta
1 (HLA-DQB1), major histocompatibility complex, class II,
DP alpha 1 (HLA-DPA1), major histocompatibility complex,
class II, DP beta 1 (HLA-DPB1), major histocompatibility
complex, class I, B (HLA-B) and low-density lipoprotein
receptor-related protein 5 (LRP5). The ‘deltaedelta Ct
method’ was used for comparing relative gene-expression
results (PE Applied Biosystems, Perkin Elmer, CA). Expres-
sion of target genes was standardized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH ) and displayed as fold-
change relative to control RNA used as the calibrator.
Statistical analysis
Statistical analyses were carried out using statistical tests
as implemented in SPSS software (version 11.5). All values
552 L. Rossi et al.were expressed as median and range. When comparing
groups, statistical significance was determined by using
non-parametric ManneWhitney test.
Results
Gene-expression profile by microarray technology
of peripheral venous whole blood
Of the 14 000 transcripts represented on our arrays, after
data processing and application of the filtering criteria, the
analysable transcripts numbered 5084.
SAM analysis showed 82 genes differentially expressed in
peripheral whole blood of CAS patients compared with
controls: 61/82 genes had increased expression and 21/82
genes showeddecreased expression in CAS patients (Table 2).
Gene ontology analysis of differentially expressed
genes in CAS patients
According to GO analysis, we observed four statistically
significant enriched biological processes associated with
CAS: ‘Major Histocompatibility Complex (MHC) class II
(antigen processing and presentation)’, ‘Oxygen Trans-
port’, ‘MHC class I (antigen processing and presentation)’
and ‘Immune Response’ (Table 3). In Table 3, differentially
expressed genes in CAS patients linked to each biological
process term are also reported.
Comparison of gene-expression profiles of CAS and
AAA patients
Comparing gene-expression profiles obtained in CAS
patients (this article) and in AAA patients (previous
article),7 we found 14 genes differentially expressed in
both CAS and AAA (Table 2 and Fig. 1). Of these 14 genes, 10
showed an increased expression and four a reduced
expression in CAS and AAA patients with respect to the
respective controls (Table 2 and Fig. 1).
By contrast, a larger number of genes showed a distinc-
tive expression signature in CAS or AAA patients, which may
therefore serve as specific signatures of disease.
Comparing the statistically significant enriched GO bio-
logical processes of CAS (Table 3) and AAA patients7
(‘oxygen transport’: HBA2, HBD, HBE1, HBQ1; ‘positive
regulation of protein kinase activity’: MAP2K3, PTPRC; and
‘lipid metabolic process’: ACADS, CIDEA, LRP5, MGLL,
ADIPOR1, HSD17B14), we found that the alteration of the
‘oxygen transport’ is a common feature of the two diseases.
On the contrary, the alteration of ‘immune response’ as
well as that of the ‘lipid metabolism’ seems to be
a distinctive signature of the CAS and AAA disease,
respectively.
Microarray data validation by RT-PCR
To validate and replicate microarray experimental results,
the messengerRNA (mRNA) expression of 14 out of 82
differentially expressed genes in CAS was investigated by
RT-PCR. We evaluated these genes in the same pools ofpatients and controls used for microarray experiments
(validation study, Table 4). Furthermore, we extended the
RT-PCR analysis of these 14 genes in two independent larger
populations of CAS patients (n Z 40) and controls (nZ 40)
(replication study, Table 4). We selected five genes that
were associated with GO terms altered only in CAS patients:
three transcripts associated to the ‘MHC class II (antigen
processing and presentation)’ and ‘immune response’ (HLA-
DPA1, HLA-DPB1, HLA-DQB1); one transcript associated
with ‘MHC class I (antigen processing and presentation)’
and ‘immune response’ (HLA-B); and one transcript asso-
ciated to the ‘immune response’ (IFIT1).
Moreover, we validated nine genes selected among the
14 genes similarly altered in CAS and AAA patients (previous
article)7 (Table 2 and Fig. 1). These nine genes are involved
in ‘oxygen transport’ (HBA2, HBE1, HBQ1), erythrocyte
membrane (EPB49 and GYPC ), B-cell development and
function as well as signalling in other white cells and
platelets (BTK ), induction of metalloproteinases (BSG),
regulation of G-protein signalling (RGS2) and lipid meta-
bolic process (LRP5).
All the mRNA levels of genes detected by RT-PCR on the
pools were consistent with the microarray experiment
(Table 4).
Concerning immune response genes, the replication of
microarray data on the larger number of CAS patients and
controls confirmed the statistically significant increased
expression of HLA-DPA1, HLA-DPB1 and HLA-DQB1 and the
significant decreased expression of HLA-B (Table 4).
RT-PCR analysis showed the significant higher expression
of HBQ1, HBE1, EPB49, GYPC and BSG in CAS patients
compared with controls. Only the HBA2 gene failed to reach
the statistical significance, even if it showed a trend to an
increased expression in patients. RGS2 and LRP5 were
confirmed to have a significant decreased expression in
patients with respect to controls (Table 4). In Fig. 2, we
showed the scatter plots of the individual DCt values of the
three most significant genes (HLA-B, BSG and RGS2).
Haematological parameters in CAS patients and
controls
To investigate the possible mechanisms and/or effects of
expression changes in erythrocyte genes, we evaluated
some haematological parameters (Table 5). CAS patients
had significantly higher values of WBC and RBC counts, Hct
and EPO plasma levels with respect to controls.
Discussion
In this article, we reported the peripheral blood gene-
expression profile of CAS patients. Moreover, we identified
common molecular pathways sustaining similar pathophys-
iological processes or novel molecular mechanisms of two
important atherosclerotic diseases, CAS and AAA, by inte-
grating systemic gene-expression data of CAS obtained in
this study with those of AAA obtained in our previous
article.7
Based on GO classification, we found that CAS patients
differentially express a large variety of transcripts involved
in immune response, antigen processing and presentation
Table 2 Genes differentially expressed in the blood of CAS patients.
Gene name Symbol Accession
Number
Gene ID d dx
Genes with increased expression in CAS patients
PDZK1 interacting protein 1 PDZK1IP1 NM_005764 10158 6.52
haemoglobin, alpha 2a HBA2 V00488 3040 4.24 5.30
Tescalcin TESC AK000614 54997 4.22
solute carrier family 25, member 39 SLC25A39 NM_016016 51629 4.20 2.88
F-box protein 7 FBXO7 AL050254 25793 4.04
guanylate kinase 1 GUK1 L76200 2987 3.58 3.52
calcium channel,voltage-dependent,gamma subunit 5 CACNG5 NM_014404 27091 3.45
haemoglobin, theta 1a HBQ1 NM_005331 3049 3.37 2.44
erythrocyte membrane protein band 4.9 (dematin)a EPB49 U28389 2039 3.31 1.93
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 X03557 3434 3.19
ATPase, Hþ transporting, lysosomal 16 kDa, V0 subunit c ATP6V0C M62762 527 3.18
haemoglobin, epsilon 1a HBE1 NM_005330 3046 3.18 3.49
minichromosome maintenance complex component 3 MCM3 AL034343 4172 3.09
ubiquitin B pseudogene 1 UBBP1 X04801 7315 3.01
family with sequence similarity 89, member B FAM89B AF052151 23625 2.99
glutathione peroxidase 1 GPX1 Y00483 2876 2.93
mitogen-activated protein kinase 3 MAP2K3 D87116 5606 2.92 1.71
ubiquitin B pseudogene 2 UBBP2 X04802 23668 2.70
immunoglobulin kappa constant IGKC M63438 3514 2.69 1.73
eukaryotic translation elongation factor 2 EEF2 Z11692 1938 2.68
ring finger protein 10 RNF10 D87451 9921 2.67
RecQ protein like 4 RECQL4 AB006532 9401 2.62
major histocompatibility complex, class II, DP betaa HLA-DPB1 X02228 3115 2.54
polymerase (RNA) III (DNA directed) (32kD) POLR3G U93868 10622 2.48
H3 histone family, member C HIST1H3C X57128 8352 2.47
BCL2-like 1 BCL2L1 Z23115 598 2.40
cyclin I CCNI AF135162 10983 2.36
sorbin and SH3 domain containing 3 SORBS3 AF037261 10174 2.31
capping protein (actin filament), gelsolin-like CAPG M94345 822 2.28
glycophorin C (Gerbich blood group)a GYPC NM_002101 2995 2.28 2.16
Basigina BSG X64364 682 2.25 1.64
procollagen-proline, 2-oxoglutarate 4-dioxygenase
(proline 4-hydroxylase), beta polypeptide
P4HB J02783 5034 2.23
T-cell receptor beta joining 2-1 TRBJ2-1 X00437 28629 2.23
GA-binding protein transcription factor, alpha subunit (60kD) GABPA U13044 2551 2.19
ribosomal protein L18 RPL18 L11566 6141 2.17
transducin (beta)-like 3 TBL3 U02609 10607 2.16
Albumin ALB M12523 213 2.12
S100 calcium-binding protein A4 (calcium protein, calvasculin,
metastasin, murine placental homolog)
S100A4 M80563 6275 2.11
solute carrier family 25, member 37 SLC25A37 AF223466 51312 2.09
asparagine-linked glycosylation 3 homolog (S. cerevisiae,
alpha-1,3-mannosyltransferase)
ALG3 Y09022 10195 2.09
guanine nucleotide binding protein
(G-protein), beta polypeptide 2-like 1
GNB2L1 M24194 10399 2.07
karyopherin alpha 4 (importin alpha 3) KPNA4 AB002533 3840 2.06
erythroid associated factor ERAF AF208865 51327 2.06
a disintegrin and metalloproteinase domain 7 ADAM7 AF090327 8756 2.05
major histocompatibility complex, class II, DR beta 3 HLA-DRB1
HLA-DRB3
HLA-DRB4
V00522 3123
3125
3126
2.04
N-myc downstream regulated NDRG1 D87953 10397 2.03
drebrin-like DBNL NM_014063 28988 2.03
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial ECHS1 D13900 1892 2.01
major histocompatibility complex, class II, DQ beta1a HLA-DQB1 M81141 3119 2.01
(continued on next page)
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Table 2 (continued )
Gene name Symbol Accession
Number
Gene ID d dx
SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 5
SMARCA5 AB010882 8467 2.01
RNA-binding protein S1, serine-rich domain RNPS1 L37368 10921 2.01
apolipoprotein L, 2 APOL2 Z95114 23780 2.00
SH3-binding domain glutamic acid-rich protein like SH3BGRL AF042081 6451 2.00
neurogranin (protein kinase C substrate, RC3) NRGN X99076 4900 1.99
trans-golgi network protein 2 TGOLN2 AF027516 10618 1.97
RBM38 RNA-binding motif protein 38 RBM38 X75315 55544 1.97
LIM homeobox protein 3 LHX3 AF156889 8022 1.96
major histocompatibility complex, class II, DP beta1a HLA-DPA1 X03100 3113 1.93
glutamic-oxaloacetic transaminase 2, mitochondrial
(aspartate aminotransferase 2)
GOT2 M22632 2806 1.93
origin recognition complex, subunit 5 (yeast homolog)-like ORC5L U92538 5001 1.89
ectonucleoside triphosphate diphosphohydrolase 5 ENTPD5 AF039918 957 1.89
Genes with decreased expression in CAS patients
neuroblastoma breakpoint family, member 12 NBPF12 AF131738 440675 6.28
AHNAK nucleoprotein (desmoyokin) AHNAK M80899 79026 5.42
cytokine receptor-like factor 1 CRLF1 AF059293 9244 5.13
suppressor of cytokine signalling 6 SOCS6 AF161545 9306 4.69
S100 calcium-binding protein A8 (calgranulin A) S100A8 X06234 6279 4.44
complement factor H-related 4 CFHL4 X98337 10877 3.86
colony stimulating factor 2 receptor, beta, low-affinity
(granulocyte-macrophage)
CSF2RB M59941 1439 3.84
coiled-coil domain containing 72 CCDC72 NM_015933 51372 3.74
low-density lipoprotein receptor-related protein 5a LRP5 AF077820 4041 3.70 3.46
early growth response 1 EGR1 AJ243425 1958 3.61
Homo sapiens Bruton’s tyrosine kinase (BTK),
alpha-D-galactosidase
A (GLA), L44-like ribosomal protein
BTK U78027 695 3.38 2.76
guanine nucleotide binding protein (G-protein), alpha13 GNA13 AF493902 10672 3.35
receptor-associated protein of the synapse, 43kD RAPSN Z33905 5913 3.34 2.46
Homo sapiens clone R2 ErbB-3 R2 (c-erbB-3) mRNA,
partial cds
ERBB3 U88358 2065 3.30
CDC-like kinase 1 CLK1 L29219 1195 3.21
chromosome 12 open reading frame 35 C12orf35 AK000703 55196 3.21
guanine nucleotide binding protein 10 GNG10 U31383 2790 3.11
major histocompatibility complex, class I, Ba HLA-B AJ250917 3106 3.11
regulator of G-protein signalling 2, 24kDa RGS2 L13463 5997 2.65 1.97
wingless-type MMTV integration site family member 2 WNT2 X07876 7472 2.52
ribosomal protein L7 RPL7 X57958 6129 2.45
d-value Z significance analysis of microarrays (SAM) t-statistic for CAS patients vs controls.
dx-value Z significance analysis of microarrays (SAM) t-statistic for AAA patients vs controls [8].
a Genes validated by real-time PCR.
554 L. Rossi et al.and oxygen transport. Whereas the differential expression
of genes involved in oxygen transport and of erythrocyte
genes, such as GYPC and EPB49, represents a common
feature between CAS and AAA patients, the differential
expression of genes involved in immune response and
antigen processing and presentation represents a distinc-
tive signature of CAS disease. CAS and AAA patients have
common risk factors, but they develop one of these two
disorders or both. Gene alterations described in this article
could explain, at least in part, this paradox.
In CAS, we found an increased expression of genes
coding components of the MHC class II antigen processingand presentation process (HLA-DPA1, HLA-DPB1, HLA-DQB1,
HLA-DRB1/3/5) and a decreased expression of genes coding
components of the MHC class I antigen processing and
presentation process (HLA-B, IGKC ). These data confirm an
activation of MHC class II molecules involved in the devel-
opment and activation of CD4þ T helper cell-dependent
immune response, and indicate a decreased expression of
MHC class I molecules involved in activation of CD8þ T cell-
dependent immune response. The increased expression of
DBLN, a gene coding an important adaptor protein that
regulates the T-cell activation and immune responses,16
and the altered expression of the two interferon-
Table 3 List of all significantly enriched GO terms among genes differentially expressed in CAS.
GO ID p N n GO Term Genes
0002504 8.02  107 11 4 MHC class II
(antigen processing
and presentation)
HLA-DPA1([), HLA-DPB1([), HLA-DQB1([),
HLA-DRB1/3/5([)
0015671 2.97  109 9 3 Oxygen Transport HBA2([), HBE1([), HBQ1([)
0002474 0.0045 14 2 MHC class I
(antigen processing
and presentation)
HLA-B(Y), IGKC(Y)
0006955 0.0047 366 8 Immune Response HLA-B(Y), HLA-DPA1([), HLA-DPB1([),HLA-DQB1([),
HLA-DRB1/3/5([),IFIT1([), IGKC (Y), DBNL ([)
n, number of differentially expressed genes annotated to the GO term; N, number of genes represented on the array annotated to the
GO term (the reference gene set is the total number of transcripts spotted in the array); p values were adjusted by using the false
discovery rate (FDR) multiple testing correction.
Gene-expression Profile of Carotid Artery Stenosis 555regulated genes, IFIT1 (increased) and SOCS6 (decreased),
suggests further cytokine signalling pathways to be inves-
tigated in CAS.
The increased expression of HLA-DPB1, HLA-DQB1 and
HLA-DRB1 was consistent with the gene-expression profiling
data obtained in the femoral atherosclerotic lesions of
patients with peripheral arterial occlusive disease (PAD).17
The predominant alteration of the immune system-related
genes and pathways observed in CAS and PAD patients, but
not in AAA patients, might suggest that up-regulation of
immune genes may be a critical signature of the athero-
sclerotic disease in femoral and carotid arteries. Moreover,
several literature data on carotid artery lesions suggest
that immune reactions with activation of T lymphocytes are
a feature of the disease.18,19
Several studies have discussed the role of inflammation
as the first step in promoting endothelial dysfunction and
progression of atherosclerotic processes. Moreover, the
auto-immune response against antigens expressed in the
endothelium and the greater prevalence of atherosclerosis
in immune-mediated rheumatic diseases such as rheuma-
toid arthritis and systemic lupus erythematosus strongly
suggest the involvement of auto-immunity in the athero-
sclerotic process.3 Several pieces of evidence suggested
that atherosclerosis could be caused by an immune reaction
against autoantigens such as oxidised low-density lipopro-
tein (LDL) and heat shock proteins (HSP).3 Auto-immuneFigure 1 Venn diagram showing the comparison between
differentially expressed genes in CAS (present paper) and AAA
patients.7mechanisms could also play a significant role in diabetes-
related atherosclerosis.20 Moreover, numerous studies have
demonstrated a pathogenetic relationship between
atherosclerosis and micro-organisms (bacteria and viruses)
causing chronic infections.20
Interestingly, the microarray profile highlights 14 genes
that might sustain common molecular alterations in CAS
and AAA. A large part of these genes, although not all, was
also validated by RT-PCR analysis in independent larger
population of patients and controls.
In particular, we found the decreased expression of the
RGS2 gene, coding one of the regulator proteins of the G-
protein signalling pathway, that could be responsible for, at
least in part, the high prevalence of hypertension in AAA
and CAS patients. RGS2 was shown to be crucial in the
regulation of vascular tone as RGS2 deficiency leads to
severe hypertension and prolonged vasoconstriction in
animal models.21 Decrease in mRNA and protein RGS2 levels
was shown in cells from hypertensive patients.22
BSG gene coding basigin or EMMPRIN, a 58-kDa
membrane glycoprotein member of the immunoglobulin
superfamily, showed an increased expression. This datum
demonstrates the increased expression in circulating cells
of this inductor of several metalloproteinases (MMPs) and,
in particular, of MMP9. This finding suggests that EMMPRIN
activation could be a mechanism of monocytes/macro-
phage MMPs expression induction either at the level of the
atherosclerotic lesion or at the systemic level. In fact,
previous data showed the up-regulation of EMMPRIN in
monocytes isolated from patients with acute myocardial
infarction, in atherosclerotic lesions from patients with CAS
and in ventricles of heart failure patients.23,24
Our data inCAS confirmed the important role of decreased
expression of LRP5 previously observed in AAA7 in which we
demonstrated an association between decreased expression
levels of LRP5 gene and increased levels of Lp(a), suggesting
the potential role of LRP5 in Lp(a) catabolism. Even if we
observed decreased expression of LRP5 in both CAS and AAA
patients, the alteration of the lipid metabolic process was
not observed in CAS patients and seems to be a distinctive
signature of the aneurysmal disease.7
Among common features in CAS and AAA patients, our
data strongly indicated the role of the alteration of a large
number of erythroblast genes involved in oxygen transport
Table 4 Fold-Change of increase or decrease in expression of genes analysed by RT-PCR in CAS patients versus controls and
d values of microarray experiments.
Gene Pooled samples from CAS patients and controls CAS patients (N Z 40) and controls (N Z 40)
Fold-Change (range) p d Fold-Change (range) p
HLA-DPA1 2.71 (2.40e3.10) 0.0009 1.93 1.51(0.70e3.23) 0.044
HLA-DPB1 3.08 (2.80e3.39) 0.0003 2.54 1.89 (0.86e4.14) 0.010
HLA-DQB1 1.95 (1.81e2.11) 0.0005 2.01 1.69 (0.80e3.63) 0.008
HLA-B 0.52 (0.49e0.55) 0.0002 3.11 0.47(0.27e0.82) 3.77  107
IFIT1 2.92(2.15e3.97) 0.001 3.19 2.10(1.45e3.03) 0.003
LRP5 0.49 (0.45e0.54) 0.001 3.70 0.51(0.25e1.04) 0.001
HBA2 2.51 (2.37e2.67) 0.001 4.24 1.78 (0.69e4.56) 0.294
HBQ1 4.01 (3.02e5.33) 0.0003 3.37 2.93 (1.36e6.15) 0.001
HBE1 2.55 (1.79e3.63) 0.0005 3.18 2.46 (0.91e6.63) 0.001
GYPC 3.33 (2.78e3.99) 0.001 2.28 2.60 (0.89e7.61) 0.046
EPB49 4.02 (3.64e4.43) 0.0008 3.31 2.69 (1.27e5.70) 0.042
BSG 4.34 (2.86e6.58) 0.001 2.25 2.69(0.99e7.31) 6.38  106
RGS2 0.44 (0.28e0.70) 0.0004 2.65 0.51(0.25e1.08) 0.0001
BTK 0.56(0.36e0.88) 0.0009 3.38 0.55(0.38e0.80) 0.015
RT-PCR Z Real-Time Polymerase Chain Reaction, d-value Z significance analysis of microarrays (SAM) t-statistic; non-parametric
ManneWhitney test was used for determining statistical significance; p values were adjusted by using the false discovery rate (FDR)
multiple testing correction.
556 L. Rossi et al.and red cell structure stability. Of particular interest were
the increased expressions of HBQ1 and HBE1, which encode
the theta and epsilon embryonic haemoglobin chains,
respectively, suggesting a switch toward the reactivation of
genes not normally expressed in adult humans. The
increased expression of haemoglobin genes could represent
a secondary response to chronic hypoxia and oxidative
stress. In addition, the increased expression of structural
erythrocyte genes, such as GYPC, might play a role in the
adaptative processes of the red cells to chronic hypoxia andHLA -B
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Figure 2 Scatter plot of the individual DCt values of the 3 most s
on the larger number of CAS patients (n Z 40) and controls (n Z
BSG Z basigin; RGS2 Z regulator of G-protein signalling 2; DCt Z
phosphate dehydrogenase (GAPDH ).haemodynamic stress. Haematological data are consistent
with those obtained by other groups concerning the strong
association of high haematocrit and blood viscosity with the
severity of carotid atherosclerosis.25,26 Due to the evalua-
tion of gene-expression in whole blood, one of the limita-
tions of our study was the variation in number and types of
the different cell populations. However, this approach
allowed us to search for markers of disease in an easily
available specimen for translational studies. Moreover, due
to the higher prevalence of traditional cardiovascular riskBSG RGS2
2 0
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.
0
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-3.0
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= CAS
ignificant genes in the replication of microarray data by RT-PCR
40). HLA-B Z major histocompatibility complex, class I, B;
Expression of target gene standardized to glyceraldehyde-3-
Table 5 Haematological parameters in CAS patients and controls.
Haematological parameters Controls (N Z 40) Patients (N Z 40) p
White Blood Cells (103/mL) 5.4 (3.0e8.3) 6.8 (4.9e13.2) 1.27  106
Red Blood Cells (106/mL) 4.5 (3.9e5.3) 4.7 (3.8e5.5) 0.036
Haemoglobin (g/dL) 13.5 (11.7e15.2) 14.2 (10.5e16.2) 0.089
Hematocrit (%) 39.4 (34.6e44.6) 43.4 (31.3e49.5) 7.60  105
Reticulocytes (%) 0.9 (0.5e1.5) 0.9 (0.1e1.5) 0.881
Erythropoietin (mU/mL) 11.5 (7.6e24.1) 14.5 (5.0e36.5) 0.014
Values of the different haematological parameters are expressed as median and range. Non-parametric ManneWhitney test was used for
determining statistical significance. A p value less than 0.05 was considered statistically significant.
Gene-expression Profile of Carotid Artery Stenosis 557factors and other clinical manifestations of atherosclerosis
in patients (coronary artery disease (CAD), peripheral
artery disease (PAD) and chronic obstructive pulmonary
disease (COPD)), we cannot confirm that the differentially
expressed genes identify biomarkers of CAS versus athero-
sclerosis. Nevertheless, the comparison of CAS and AAA
gene-expression signatures represents an indirect response
to this issue.
For a large part of genes differentially expressed in
whole blood (beyond those commented upon), few data are
available on their expression in CAS patients’ arterial
tissue. Further studies are needed to evaluate this issue
and analyse whether these findings reflect the biological
changes in the artery itself.
Conclusion
In conclusion, our data identify novel molecular alterations
possibly involved in the pathogenesis of CAS. GO analysis
identified a statistically significant enrichment in CAS of
differentially expressed transcripts involved in immune
response and oxygen transport. Whereas alteration of
oxygen transport is a common tract of the two localisations
(CAS and AAA), alteration of immune response in CAS and of
lipid metabolic process in AAA represents distinctive tracts
of the two atherosclerotic diseases.
Our study brings to light several novel genes that need
a strong effort to better comprehend their involvement in
the pathophysiology of CAS and AAA and their possible role
as markers of progression or targets for therapeutic
intervention.
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